ROP.SW Roche Holding AG
SIXHealthcareAs of 2026-06-01 09:34
Valuation
View DetailsP/E (TTM)
19.89
PEG
—
P/B
7.58
P/S
4.17
EV/EBITDA
12.46
DCF Value
—
FCF Yield
4.6%
Div Yield
3.0%
Margins & Returns
Gross Margin
73.5%
Operating Margin
28.9%
Net Margin
20.9%
ROE
41.2%
ROA
12.8%
ROIC
18.8%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $30.57B | $5.47B | $6.81 |
| Q2 2025 | $30.94B | $7.41B | $9.23 |
| Q4 2024 | $31.64B | $2.02B | $2.52 |
| Q2 2024 | $30.76B | $6.26B | $7.78 |
Listing Info
Market
US
Exchange
SIX
Currency
USD
Sector
Healthcare
Industry
Drug Manufacturers - General
Country
CH
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Switzerland, Germany, the United States, Austria, Netherlands, the United Kingdom, France, Belgium, and internationally. The company offers pharmaceutical products for treating oncology, neuroscience, infectious, immunology, cardiovascular and metabolism, ophthalmology, and respiratory, as well as anemia, cancer, dermatology, hemophilia, inflammatory and autoimmune, neurological, and transplantation. It also offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases. In addition, the company supplies diagnostic instruments and reagents. It has a research collaboration agreement with Synlogic, Inc. for the discovery of a novel synthetic biotic for the treatment of inflammatory bowel disease (IBD). The company was founded in 1896 and is headquartered in Basel, Switzerland.